Pandion Therapeutics, Inc.
DelistedCIK 1807901fmd_1JTM9F9B3DH44K94YMJV2C9S6CManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Dec 31, 2020, 8 periods
Latest annual · FY2020
Millions- Total revenues
- 9
- Operating income
- (38)
- Net income
- (38)
- Free cash flow
- (38)
Latest quarter · Q4 FY2020
Millions- Total revenues
- 2
- Operating income
- (11)
- Net income
- (11)
- Free cash flow
- (12)
Pandion Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Revenue | $8.8 million | $967,000 | +807.9% | 10-K 2021-03-12 · proof |
| Operating income | -$37.9 million | -$22.2 million | 10-K 2021-03-12 · proof | |
| Net income | -$38.1 million | -$21.9 million | 10-K 2021-03-12 · proof | |
| Cash from operating activities | -$35 million | -$13.4 million | 10-K 2021-03-12 · proof | |
| Free cash flow | -$37.8 million | -$14.1 million | 10-K 2021-03-12 · proof | |
| Total assets | $227.9 million | $21 million | +984.1% | 10-K 2021-03-12 · proof |
| Total liabilities | $13.1 million | $16.8 million | -22% | 10-K 2021-03-12 · proof |
| Cash and cash equivalents | $219.9 million | $16 million | +1,276.9% | 10-K 2021-03-12 · proof |
- What was Pandion Therapeutics, Inc.'s revenue in fiscal 2020?
- Pandion Therapeutics, Inc. reported revenue of $8.8 million for fiscal 2020 (the year ended Dec 31, 2020), against $967,000 the year before (+807.9%). Source: the 10-K filed with the SEC on Mar 12, 2021. SEC
- What was Pandion Therapeutics, Inc.'s operating income in fiscal 2020?
- Pandion Therapeutics, Inc. reported operating income of -$37.9 million for fiscal 2020 (the year ended Dec 31, 2020), against -$22.2 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2021. SEC
- What was Pandion Therapeutics, Inc.'s net income in fiscal 2020?
- Pandion Therapeutics, Inc. reported net income of -$38.1 million for fiscal 2020 (the year ended Dec 31, 2020), against -$21.9 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2021. SEC
- What was Pandion Therapeutics, Inc.'s cash from operating activities in fiscal 2020?
- Pandion Therapeutics, Inc. reported cash from operating activities of -$35 million for fiscal 2020 (the year ended Dec 31, 2020), against -$13.4 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2021. SEC
- What was Pandion Therapeutics, Inc.'s free cash flow in fiscal 2020?
- Pandion Therapeutics, Inc. reported free cash flow of -$37.8 million for fiscal 2020 (the year ended Dec 31, 2020), against -$14.1 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2021. SEC
- What are Pandion Therapeutics, Inc.'s total assets?
- As of Dec 31, 2020, Pandion Therapeutics, Inc. reported total assets of $227.9 million, against $21 million a year earlier (+984.1%). Source: the 10-K filed with the SEC on Mar 12, 2021. SEC
- What are Pandion Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2020, Pandion Therapeutics, Inc. reported total liabilities of $13.1 million, against $16.8 million a year earlier (-22%). Source: the 10-K filed with the SEC on Mar 12, 2021. SEC
- What are Pandion Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2020, Pandion Therapeutics, Inc. reported cash and cash equivalents of $219.9 million, against $16 million a year earlier (+1,276.9%). Source: the 10-K filed with the SEC on Mar 12, 2021. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1807901&period_type=annual&limit=5"Information only, not investment advice.